Screener
Protagonist Therapeutics PTGX Accrued Expenses
Accrued Expenses at other companies
Other financials
Where this comes from
Reported directly by Protagonist Therapeutics in its filing.
Tagged under the XBRL concept us-gaap:OtherAccountsPayableAndAccruedLiabilities.
The source filing: Protagonist Therapeutics’s 10-Q, filed August 5, 2026.
- Filed
- Aug 5, 2026, 4:17 PM EDT
- Fiscal quarter
- Q2 FY2026
- Calendar quarter
- Q2 2026
- Accession
- 0001104659-26-091123
| Line item | June 30, 2026 | December 31, 2025 |
|---|---|---|
| Liabilities and Stockholders’ Equity | ||
| Current liabilities: | ||
| Accounts payable | $3,459 | $5,339 |
| Accrued expenses and other payables | 21,667 | 28,269 |
| Deferred revenue | 9,659 | 9,550 |
| Operating lease liability | 2,396 | 2,283 |
| Total current liabilities | 37,181 | 45,441 |
| Operating lease liability - noncurrent | 6,820 | 8,040 |
Item 1. Condensed Consolidated Financial Statements (unaudited)
FAQ
- What is Protagonist Therapeutics's accrued expenses?
- Protagonist Therapeutics (PTGX) reported accrued expenses of $21.67M in Q2 2026.
- How has Protagonist Therapeutics's accrued expenses changed year-over-year?
- Protagonist Therapeutics's accrued expenses increased by 40.7% year-over-year, from $15.4M to $21.67M.
- What is the long-term trend for Protagonist Therapeutics's accrued expenses?
- Over 5 years (2020 to 2025), Protagonist Therapeutics's accrued expenses has grown at a 8.9% compound annual growth rate (CAGR), from $18.5M to $28.27M.
- What does accrued expenses mean?
- Expenses incurred but not yet paid or invoiced — interest accruals, tax accruals, warranty reserves, and other timing differences.
Ask your AI about Protagonist Therapeutics's accrued expenses.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude